These results demonstrate that 4E-BP3 is an important downstream effector of mTORC1 under prolonged mTORC1 inhibition and, thereby, may serve as a predictor of anti-mTOR drug efficacy in cancer therapy. The gene discussed is MTOR; the disease is cancer.